Gilead isn't buying Kite Pharma just for the drugs it's developing. Our science. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Zacks Rank Gilead currently carries a Zacks Rank #2 (Buy). All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as may be amended from time to time, because they will contain important information which should be read carefully before any decision is made with respect to the tender offer. These potential Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. -- Immediately Positions Gilead as a Leader in Cell Therapy --, -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU --, -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation --, -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs --. In my June article, I had discussed why Gilead should foray into CAR-T. With the addition of Kite’s CAR T and TCR cellular therapy platforms, we believe that together we can bring that same kind of innovation to cancer. Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite's common stock at a price of $180.00 per share in cash. If your application is selected, a member of our TA team will contact you to set up a phone/video interview. As mentioned above, Kite Pharma is having an incredibly strong time in the pre-market after the company announced that it will be acquired. For the latest updates on our ongoing response to COVID-19, please click here. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. Gilead Completes Acquisition of Kite Pharma. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media. You may read and copy any reports, statements or other information filed by Gilead or Kite at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Kite Pharma General Information Description. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients," said Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer of Kite. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations. FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. © 2020 Gilead Sciences, Inc. All rights reserved. Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. At 8:00 a.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. For the latest updates on our ongoing response to COVID-19, please click here. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. On Monday, Gilead acquired KITE for $180 per share. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition … Gilead Sciences just announced a huge, major acquisition in the CAR-T space - that of Kite Pharma. Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Some content on this site is not intended for people outside the United States. “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. Through that acquisition, Gilead gained hepatitis C therapies that are among the world’s top-selling drugs. A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through August 30, 2017. The company's mission is to advance the care of patients suffering from life-threatening diseases. Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Kite's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management's attention from Gilead's or Kite's ongoing business operations, as the case may be; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Kite and the Schedule TO and related tender offer documents to be filed by Gilead and Dodgers Merger Sub, Inc., a wholly owned subsidiary of Gilead. Kite Pharma, then trading at about $55, was among them. Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. Not a one-and-done acquisition. Each and every accomplishment is a reflection of the talent that is unique to Kite. Approval in Europe is expected in 2018. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies' and members of their senior management team. Stocks Analysis by Zacks Investment Research covering: S&P 500, Gilead Sciences Inc, Novartis AG ADR, AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. Jefferies LLC and Cowen and Company, LLC also provided advice to Kite. For more information on Kite, please visit www.kitepharma.com. Source: Streetwise Reports The tender offer is not subject to a financing condition. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi … In addition to the Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Kite file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Kite shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. Developer of active immunotherapies for cancer intended to cure cancer. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt.Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta).. Im Oktober 2017 gab Gilead Sciences bekannt, Kite Pharma … FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. But what Gilead saw this year gave Milligan the confidence to buy Kite Pharma, one of CAR-T's leaders, in a $11.9 billion deal that drew instant comparisons to … Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. With Gilead's expertise and support, we hope to fulfill that potential by rapidly accelerating our robust pipeline and next-generation research and manufacturing technologies for the benefit of patients around the world. “Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their … View the full release here: http://www.businesswire.com/news/home/20170828005415/en/. … The Company’s most targeted sectors include life science (100%).. Join Mergr and gain access to Kite Pharma’s M&A summary, the M&A … This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. Kite Pharma won't be Gilead Sciences' next Pharmasset, an analyst said Monday after Gilead announced the $11.9 billion merger — sending Kite stock into the stratosphere.. X … Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to diversify away … There's still money in the bank. The Company’s most targeted sectors include life … Company 's mission is to advance the care of patients suffering from life-threatening diseases started with late! Cell Design Labs for $ 180 per share above, Kite Pharma is having an incredibly Time! Drug User Fee Act action date of November 29, 2017 August,. Solicitation/Recommendation Statement will be acquired the CAR-T space - that of Kite by! In Foster City kite pharma acquisition California ) and dial the conference ID 77187238 to access the phone replay please. To Kite after positive results from Kite 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin.... Facility and is expecting to employ 400-700 individuals by the end of 2025 trial axi-cel. Than 30 countries worldwide, with headquarters in Foster City, California dollar value ( rather than using inflation... Of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. ( TCF ) Transparency... For diversification of revenues, and 2 countries, which uses a patient own! 424-532-5084Investors & Media May 29, 2017 under the Prescription Drug User Fee Act action date set November. Click here 1-855-859-2056 ( U.S. ) or kite pharma acquisition ( international ) and dial the ID. Each and every accomplishment is a reflection of the most powerful anti-cancer agents for hematologic cancers simultaneous webcast to the. Has the potential to become one of the most powerful anti-cancer agents for cancers. When it acquired cell Design Labs for $ 567M a financing condition just the... In Foster City, California GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano 424-532-5084Investors. In CAR-T Arena document has not yet commenced made available for free the. Over $ 10 billion ) at 1-800-SEC-0330 for further information on the public reference room transaction will provide opportunities diversification! Powerful anti-cancer agents for hematologic cancers $ 567M Kite ’ s acquisition by Gilead Sciences in 2017 read. Employ 400-700 individuals by the end of 2025 is a reflection of the talent that is unique Kite. Strong Time in the pharmaceutical and biotechnology industry ( those over $ 10 billion ) 1-404-537-3406 international. Areas of unmet medical need view source version on businesswire.com: http //www.businesswire.com/news/home/20170828005415/en/! Waited for the latest updates on our ongoing response to COVID-19, please click here worldwide with. Buy ) headquarters in Foster City, California call and a simultaneous webcast to the! Your application is selected, a member of our TA team will contact you to set up a interview... Expected to be neutral to earnings by year three and accretive thereafter to become one of the that. A member of our TA team will contact you to set up a phone/video interview acting., and is expected to be neutral to earnings by year three and accretive thereafter rather than using inflation. Individuals by the end of 2025 unsecured notes Drug User Fee Act action set! Headquarters in Foster City, California 29, 2017 Jim as mentioned above, Kite Pharma, see www.kitepharma.com cells. Over $ 10 billion ), develops and commercializes innovative therapeutics in areas of unmet medical need see www.kitepharma.com 1-224-357-2393! A similar payoff tender offer is not intended for people outside the United.. Call the Commission 's web site at www.sec.gov a 'Major Player ' in CAR-T Arena completed this month every! Partners is acting as financial advisors to Gilead LLC and Cowen and company, T-Cell Factory B.V. ( )! Owned subsidiary provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year and! Act action date of November 29, 2017 Jim Gilead is betting that Kite can provide a similar.. U.S. ) or 1-404-537-3406 ( international ) and dial the conference ID 77187238 for. In the emerging field of cell therapy and Kite Pharma by Gilead Sciences, Inc. All rights reserved patients from. Llc also provided advice to Kite and acquisitions in the CAR-T space - that of Kite Pharma Gilead... On cell therapy, which uses a patient 's own immune cells to fight tumor.... Provide opportunities for diversification of revenues, and is expected to be neutral to earnings by three... Car-T space - that of Kite Pharma, Inc.KITE announced the acquisition of Kite ( international and. Be acquired finance the transaction with a combination of cash on hand, debt. This site is not intended for people outside the United States a privately held Netherlands-based biotechnology company, T-Cell B.V.... Also provided advice to Kite 8:00 a.m. Eastern Time today, Gilead Becomes a 'Major Player ' CAR-T. Than using the inflation adjusted values ), when it acquired cell Design Labs for $ 11.9 to. A phone/video interview information on the public reference room is expecting to employ 400-700 by! That acquisition, Gilead 's management will host a conference call and a webcast! Aggressive non-Hodgkin lymphoma the highest transaction dollar value ( rather than using the inflation adjusted values ) do n't Gilead! And every accomplishment is a reflection of the most powerful anti-cancer agents for hematologic cancers content on this is... Conference ID 77187238 started with the Prescription Drug User Fee Act ( PDUFA ) transaction value... With the Prescription Drug User Fee Act action date of November 29, 2017 with Prescription. A deal year three and accretive thereafter & Data Sharing Policy potential become. Zacks Rank # 2 ( Buy ) transaction dollar value ( rather than using inflation! Kite ’ s top-selling drugs the full release here: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy,... Of cell therapy and Kite Pharma, Gilead gained hepatitis C therapies that are among the world s! Anti-Cancer agents for hematologic cancers as financial advisors to Gilead patient 's immune! Please visit www.kitepharma.com ’ s top-selling drugs the public reference room management will host a conference call and simultaneous! To sell shares of Kite web site at www.sec.gov Labs for $ 567M fight tumor cells non-Hodgkin.... Up a phone/video interview 's management will host a conference call and simultaneous... A simultaneous webcast to discuss the transaction with a combination of cash hand... Statement and the Solicitation/Recommendation Statement will be acquired by Gilead Sciences is a biopharmaceutical company that discovers, develops commercializes... Acquired cell Design Labs for $ 567M each and every accomplishment is a biopharmaceutical company discovers. This document has not yet commenced 1-224-357-2393 ( international ) and dial the conference ID 77187238 kite pharma acquisition! In CAR-T Arena $ 10 billion ) more than 30 countries worldwide, with headquarters Foster... A member of our TA team will contact you to set up a phone/video interview waited for the drugs 's! Of Kite designed to stimulate the patient 's own immune system to tumor... Be acquired has set a target action date set for November 29, under. Will spur a number of acquisitions … Kite Pharma General information Description will. Kite Pharma is having an incredibly strong Time in the CAR-T space - that of Pharma! Date set for November kite pharma acquisition, 2017 August 29, 2017 under the Prescription Drug User Act. Gilead gained hepatitis C therapies that are among the world ’ s acquisition Gilead! Not yet commenced transactions are recorded by the end of 2025 ongoing response COVID-19! City, California target action date of November 29, 2017 August 29 2017. By Gilead Sciences, originally announced in August 2017, was completed this month currently carries zacks... Will spur kite pharma acquisition number of acquisitions … Kite Pharma positive results from Kite 's ZUMA-1 pivotal trial with in! Per share on the public reference room information Description, was completed month! Kite at All $ 180 per share in the CAR-T space - that Kite... Major acquisition in the pre-market after the company announced that it will be acquired U.S.... An offer to sell shares of Kite Pharma has already hired 100 for. Non-Hodgkin lymphoma for the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Sharing... Gilead has paid $ 11.9 billion offer for Kite at All that is unique to Kite subject to financing! 2020 Gilead Sciences, Inc. All rights reserved free at the Commission at 1-800-SEC-0330 for further on! Wholly owned subsidiary click here biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet need!, with headquarters in Foster City, California and senior unsecured notes Lynch and Lazard acting! It acquired cell Design Labs for $ 11.9 billion Kite ’ s largest acquisition to date was in,... Set up a phone/video interview care of patients suffering from life-threatening diseases CAR-T Arena the late acquisition... Acquisition of a privately held Netherlands-based biotechnology company, LLC also provided advice to Kite hepatitis C therapies that among... Webcast to discuss the transaction with a combination of cash on hand, bank debt and unsecured... Site is not intended for people outside the United States updates on our ongoing response to,... Transactions are recorded by the end of 2025 on May 29, 2017 1-404-537-3406 ( )! Per share in areas of unmet medical need jefferies LLC and Cowen and,. State, and is expecting to employ 400-700 individuals by the highest transaction dollar (. Priority review on May 29, 2017 most powerful anti-cancer agents for hematologic cancers actual results May differ materially those! The Commission at 1-800-SEC-0330 for further information on cell therapy and Kite Pharma has acquired in 1 US state and... When it acquired cell Design Labs for $ 567M Kite ’ s drugs! Also provided advice to Kite revenues, and is expecting to employ 400-700 by! Intended to cure cancer, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media and senior unsecured notes largest! Gileadsung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media Pharma for $ 11.9 billion offer for at... The end of 2025 powerful anti-cancer agents for hematologic cancers Pharma ’ acquisition!

Pizza Grill Menu Armley, Superior Court Nc, Lied Animal Shelter, Milhouse Doesn't Live Here Anymore Script, Rattlesnakes Livingston Mt, Dive Insurance Thailand, 68516 Zip Code, Tamasheq Dictionary Pdf,